The Zacks Analyst Blog Doximity, Omnicell, Embecta, Cencora and EDOC

Published on 23 Jan 2025 on Zacks · via Yahoo Finance

COR’s fiscal 2025 expected earnings growth rate is pegged at 8.9%. The stock carries a Zacks Rank #2...

Read the rest of the article

Start tracking your investments with Statfolio

RVTY's fourth-quarter results are likely to reflect decent performance in the Diagnostics segment...

Zacks · via Yahoo Finance 29 Jan 2025

The Zacks Consensus Estimate for Merit Medical’s fourth-quarter EPS is expected to increase 2.47%...

Zacks · via Yahoo Finance 29 Jan 2025

Zacks Rank We also need to consider the stock's Zacks Rank, as this supersedes any trend on the...

Zacks · via Yahoo Finance 29 Jan 2025

We recently published a list of Jim Cramer’s Latest Calls: 10 Stocks to Buy or Sell. In this...

Insider Monkey · via Yahoo Finance 26 Jan 2025

COR’s fiscal 2025 expected earnings growth rate is pegged at 8.9%. The stock carries a Zacks Rank...

Zacks · via Yahoo Finance 23 Jan 2025

Masimo’s Price Performance Shares of the company have gained 28.4% between Sept...2 (Buy). A few...

Zacks · via Yahoo Finance 20 Jan 2025

It has a VGM Score of B. Raymond James carries a Zacks Rank #2. Cencora: Chesterbrook, PA-based...

Zacks · via Yahoo Finance 16 Jan 2025

MMSI’s Price Performance Shares of the company have lost 0.9% between Oct...2 (Buy). A few other...

Zacks · via Yahoo Finance 16 Jan 2025

Image Source: Zacks Investment Research Stocks to Consider Some better-ranked stocks in the Medic...

Zacks · via Yahoo Finance 15 Jan 2025

The GARP strategy helps investors gain exposure to stocks that have impressive prospects and are...

Zacks · via Yahoo Finance 14 Jan 2025